Mechanisms of Raynaud's disease

Vascular Medicine

Volumn 10, Issue 4, 2005, Pages 293-307

  Cooke, John P ^a   Marshall, Janice M ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Acrocyanosis; Alpha adrenoreceptors; Endothelium; Estrogen; Thermoregulation; Vasospasm

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR; CALCITONIN GENE RELATED PEPTIDE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; FLUOXETINE; KETANSERIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN SYNTHASE; SEROTONIN; THROMBOXANE; THROMBOXANE A2; VASOCONSTRICTOR AGENT;

ACROCYANOSIS; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RESPONSE; CLINICAL FEATURE; COLD SENSITIVITY; CYANOSIS; DEGRADATION; DIGITAL ARTERY; DISEASE ASSOCIATION; DISEASE EXACERBATION; EMOTION; FINGER; FOOT; HABITUATION; HAND; HUMAN; HYPEREMIA; LIMB BLOOD FLOW; LIVEDO RETICULARIS; MEDICAL DECISION MAKING; NERVE CONDUCTION; OXIDATIVE STRESS; PAIN; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SENSORY NEUROPATHY; SEX DIFFERENCE; SKIN BLOOD FLOW; STRESS; SYMPATHETIC NERVE; TREATMENT PLANNING; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ENDOTHELINS; ENDOTHELIUM, VASCULAR; FEMALE; HABITUATION, PSYCHOPHYSIOLOGIC; HUMANS; MALE; MUSCLE, SKELETAL; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NOREPINEPHRINE; OXIDATIVE STRESS; RAYNAUD DISEASE; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; SEROTONIN; SEX FACTORS; SKIN; TEMPERATURE; VASOCONSTRICTION;

EID: 31344451321     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x05vm639ra     Document Type: Review

References (94)

1. Raynaud M. On local asphyxia and symmetrical gangrene of the extremities [1862]. New researches on the nature and treatment of local asphyxia of the extremities [1874]. In: Barlow T, trans. Selected monographs. London: New Sydenham Society, 1988.
2. Cooke JP, Dzau VJ. The pathophysiology of vasospasm. In: Loscalzo J, Creager MA, Dzau VJ (eds). Textbook of vascular medicine. Boston: Little, Brown & Co., 1996: 369-86.
3. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
4. Shaun T, O'Keefe MB, Nicholas P, Tsapatsaris MD, Beetram WP Jr. Increased prevalence of migraine and chest pain in patient's with primary Raynaud's disease. Ann Intern Med 1992; 116: 985-89.
5. Smyth AE, Hughes AE, Bruce IN, Bell AL. A case-control study of candidate vasoactive mediator genes in primary Raynaud's phenomenon. Rheumatology (Oxford) 1999; 38: 1094-98.
6. Lewis T. The pathological change in the arteries supplying the fingers in warm handed people and in cases of so-called Raynaud's disease. Clin Sci 1938; 3: 287-311.
7. Bukhari M, Henick AL, Moore T, Manning J, Jayson MI. Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis. Br J Rheumatol 1996; 35: 1127-31.
8. Maricq HR, Weinrich MC, Keil JE, LeRoy EC. Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire. J Chronic Dis 1986; 39: 423-27.
9. Planchon B, Pistorius MA, Beurrier P, De Faucal P. Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients. Angiology 1994; 45: 677-86.
10. Freedman RR, Mayes MD. Familial aggregation of primary Raynaud's disease. Arthritis Rheum 1996; 39: 1189-91.
11. Creager MA. Vasospastic disease of the extremity. In: Loscalzo J, Creager MA, Dzau VJ (eds). Textbook of vascular medicine. Boston: Little, Brown & Co., 1996: 369-86.
12. Coffman JD, Cohen AS. Total and capillary fingertip blood flow in Raynaud's phenomenon. N Engl J Med 1971; 285: 259-63.
13. Hines EA, Christensen NA. Raynaud's disease among men. JAMA 1945; 129: 1
14. Cooke JP, Creager MA, Osmundson PJ, Shepherd JT. Sex differences in control of cutaneous blood flow. Circulation 1990; 82: 1607-15.
15. Gifford RW, Hines EA Jr. Raynaud's disease among women and girls. Circulation 1951; 16: 1012-21.
16. Bollinger A, Schlumpf M. Finger blood flow in healthy subjects of different age and sex and in patients with primary Raynaud's disease. Acta Chir Scand Suppl 1976; 465: 42-47.
17. Kronenberg F, Cote LJ, Linkie DM, Dyenfurth I, Downey JA. Menopausal hot flashes: thermoregulatory, cardiovascular, and circulating catecholamine and LH changes. Maturitas 1984; 6: 31-43.
18. Freedman RR, Girgis R. Effects of menstrual cycle and race on peripheral vascular alpha-adrenergic responsiveness. Hypertension 2000; 35: 795-99.
19. Fulton CT, Stallone JN. Sexual dimorphism in prostanoid-potentiated vascular contraction: roles of endothelium and ovarian steroids. Am J Physiol Heart Circ Physiol 2002; 283: H2062-73.
20. Miller VM, Vanhoutte PM. 17 beta-Estradiol augments endothelium-dependent contractions to arachidonic acid in rabbit aorta. Am J Physiol 1990; 258 (6 Pt 2): R1502-507.
21. Paredes-Carbajal MC, Juarez-Oropeza MA, Ortiz-Mendoza CM, Mascher D. Effects of acute and chronic estrogenic treatment on vasomotor responses of aortic rings from ovariectomized rats. Life Sci 1995; 57: 473-86.
22. Lewis T. Experiments relating to the peripheral mechanism involved in spasmodic arrest of circulation in fingers, a variety of Raynaud's disease. Heart 1929; 15: 7-11.
23. Lewis T, Pickering GW. Observations upon maladies in which the blood supply to the digits cease intermittently or permanently, and upon bilateral gangrene of digits; observations relevant to so-called Raynaud's disease. Clin Sci 1934; 1: 327.
24. Coffman JD, Cohen RA. Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur J Clin Invest 1988; 18: 309-13.
25. Lindblad LE, Ekenvall L. Alpha-adrenoceptors in the vessels of human finger skin. Acta Physiol Scand 1986; 128: 219-22.
26. Flavahan NA, Cooke JP, Shepherd JT, Vanhoutte PM. Human postjunctional alpha-1 and alpha-2 adrenoceptors; differential distribution in arteries of the limbs. J Pharmacol Exp Ther 1987; 241: 361-65.
27. Cooke JP, Creager SJ, Scales KM et al. Role of digital artery adrenoceptors in Raynaud's disease. Vasc Med 1997; 2: 1-7.
28. Cooke JP. Alpha adrenergic receptors in vascular smooth muscle: characterization of subtypes and modulation of response by alteration in temperature and calcium availability (thesis). Rochester, MN: Mayo Graduate School, 1984.
29. Somlyo AP, Devine CE, Somlyo AV, North SR. Sarcoplasmic reticulum and the temperature dependent contraction of smooth muscle in calcium-free solutions. J Cell Biol 1971; 51: 722-41.
30. Vanhoutte PM, Verbeuren TJ. Depression by local cooling of 3H-norepinephrine release evoked by nerve stimulation in cutaneous veins. Blood Vessels 1976; 13: 92-99.
31. Greenfield ADM, Shepherd JT, Whelan RF. Cold vasoconstriction and vasodilatation. Irish J Med Sci 1951; 309: 415-19.
32. Vanhoutte PM, Shepherd JT. Effect of temperature on reactivity of isolated cutaneous veins of the dog. Am J Physiol 1970; 218: 187-90.
33. Janssens WJ, Vanhoutte PM. Instantaneous changes of alpha-adrenoceptor affinity caused by moderate cooling in canine cutaneous veins. Am J Physiol 1978; 234: H330-37.
34. Cooke JP, Shepherd JT, Vanhoutte PM. The effect of warming on adrenergic neurotransmission in canine cutaneous vein. Circ Res 1984; 54: 547-53.
35. Flavahan NA, Lindblad LE, Verbeuren TJ, Shepherd JT, Vanhoutte PM. Cooling and a1- and a2-adrenergic responses in cutaneous veins: role of receptor reserve. Am J Physiol 1985; 249: H950-55.
36. Faber JE. Effect of local tissue cooling on microvascular smooth muscle and postjunctional a2-adrenoceptors. Am J Physiol 1988; 255: H121-30.
37. Ekenvall L, Lindblad LE, Norbach O, Etzell B-M. α-Adrenoceptors and cold induced vasoconstriction in human finger skin. Am J Physiol 1988; 255: H1000-1003.
38. Freedman RR, Sabbarwal SC, Moten M, Migaly P. Local temperature modulates alpha1- and alpha2-adrenergic vasoconstriction in men. Am J Physiol 1992; 263: H1197-200.
39. Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000; 278: H1075-83.
40. Bailey SR, Eid AH, Mitra S, Flavahan S, Flavahan NA. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res 2004; 94: 1367-74.
41. Keenan EJ, Porter JM. A2-adrenergic receptors in platelets from patients with Raynaud's syndrome. Surgery 1983; 94: 204-209.
42. Coffman JD, Cohen RA. A2-adrenergic and 5-HT2 receptor hypersensitivity in Raynaud's phenomenon. J Vasc Med Biol 1990; 2: 100-106.
43. Freedman RT, Baer RP, Mayes MD. Blockade of vasospastic attacks by a2-adrenergic but not a1-adrenergic antagonists in idiopathic Raynaud's disease. Circulation 1995; 92: 1448-51.
44. Flavaban NA, Flavahan S, Liu Q et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000; 43: 1886-90.
45. Harker CT, Vanhoutte PM. Cooling the central ear artery of the rabbit: myogenic and adrenergic responses. J Pharmacol Exp Ther 1988; 245: 89-93.
46. 2C-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004; 50: 3994-4001.
47. Tham S, Grossman JA. Limited microsurgical arteriolysis for complications of digital vasospasm. J Hand Surg [Br] 1997; 22: 359-61.
48. Marshall JM. Cardiovascular changes associated with behavioural alerting. In: Jordan D, Marshall JM (eds). Cardiovascular Regulation London: Portland Press, 1995: 61-76.
49. Edwards CM, Marshall JM, Pugh M. Lack of habituation of the pattern of cardiovascular response evoked by sound in subjects with primary Raynaud's disease. Clin Sci 1998; 95: 244-60.
50. Edwards CM, Marshall JM, Pugh M. Cardiovascular responses evoked by mild cool stimuli in primary Raynaud's disease: the role of endothelin. Clin Sci 1999; 96: 577-88.
51. Edwards CM, Marshall JM, Pugh M. The cutaneous vasoconstrictor response to venous stasis is normal in patients with primary Raynaud's disease. Clin Autonom Res 1999; 9: 255-62.
52. Henriksen O. Local sympathetic reflex mechanism in regulation of blood flow in human subcutaneous adipose tissue. Acta Physiol Scand suppl 1977; 450: 1-48.
53. Zbrozyna AW, Krebbel F. Habituation of the cold pressor response in normo- and hypertensive human subjects. Eur J Appl Physiol Occup Physiol 1985; 54: 136-44.
54. Seibold JR, Terrigino CA. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold-induced vasoconstriction in primary Raynaud's phenomenom. J Rheumatol 1986; 13: 337-40.
55. Biondi ML, Marasini B, Bianchi E et al. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenom. Int J Cardiol 1988; 19: 335-39.
56. Coffman JD, Cohen RA. Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenom. Clin Sci 1994; 86: 269-73.
57. Coleiro B, Marshall SE, Denton CP et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001; 40: 1038-43.
58. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent constrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-15.
59. Zamora MR, O'Brien RF, Rutherford RB et al. Serum endothelin-1 concentration and cold provocation in primary Raynaud's phenomenon. Lancet 1990; 336: 1144-47.
60. Fyhrquist F, Saonmaa O, Metsarinne K et al. Raised plasma endothelin-1 concentration following cold pressor test. Biochem Biophys Res Commun 1990; 169: 217-29.
61. Smyth AE, Bell AL, Bruce IN, McGrann S, Allen JA. Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. Ann Rheum Dis 2000; 59: 870-74.
62. Warner TD, Mitchell JA, de Nucci G, Vane JR. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol 1989; 13 (suppl 5): S85-88; discussion S102.
63. Romero LI, Zhang DN, Cooke JP et al. Differential regulation (expression) of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. Vasc Med 2000; 5: 147-58.
64. Edwards CM, Marshall JM. Cutaneous vasodilator responses to sodium nitroprusside but not those to acetylcholine may be impaired in patients with Primary Raynaud's Disease. Clin Auto Res 1999; 9: 35.
65. Morris SJ, Shore AC. Skin blood flow responses to the iontophoresis of acetylcholine and sodium nitroprusside in man: possible mechanisms. J Physiol 1996; 496: 531-42.
66. Khan F, Litchfield SJ, McLaren M et al. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenom. Arthritis 1997; 40: 352-57.
67. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271 (5 Pt 1): C1424-37.
68. Cooke JP. The pivotal role of nitric oxide for vascular health. Can J Cardiol 2004; 20 (suppl B): 7B-15B.
69. Lefer DJ, Granger DN. Oxidative stress and cardiac disease. Am J Med 2000; 109: 315-23.
70. Denton CP, Bunce TD, Darado MB et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology (Oxford) 1999; 38: 309-15.
71. Kellogg DL Jr, Zhao JL, Coey U, Green JV. Acetylcholine-induced vasodilation is mediated by nitric oxide and prostaglandins in human skin. J Appl Physiol 2005; 98: 629-32.
72. Khan F, Coffman JD. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon. Circulation 1994; 89: 1183-88.
73. Easter MJ, Marshall JM. Contribution of prostanoids to endothelium-dependent vasodilatation in the digital circulation of women with primary Raynaud's disease. Clin Sci 2005; 109: 45-54.
74. Taddei S, Virdis A, Ghiadoni L et al. Menopause is associated with endothelial dysfunction in women. Hypertension 1996; 28: 576-82.
75. Virdis A, Ghiadoni L, Pinto S et al. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation 2000; 101: 2258-63.
76. Taddei S, Virdis A, Mattei P et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997; 29: 736-43.
77. Hendry RG, Marshall JM.Vasoconstrictor products of cyclo-oxygenase activity limit acetylcholine-induced cutaneous vasodilatation in young men. Clin Sci (Lond) 2004; 107: 323-30.
78. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002; 23: 665-86.
79. Jun SS, Chen Z, Pace MC, Shaul PW. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium. J Clin Invest 1998; 102: 176-83.
80. Fraenkel L, Zhang Y, Chaisson CE, Evans SR, Wilson PW, Felson DT. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 1998; 129: 208-11.
81. Katusic ZS, Shepherd JT. Endothelium-derived vasoactive factors: II.endothelium-dependent contraction. Hypertension 1991; 18 (5 suppl): III86-92.
82. Hibino M, Okumura K, Iwama Y et al. Oxygen-derived free radical-induced vasoconstriction by thromboxane A2 in aorta of the spontaneously hypertensive rat. J Cardiovasc Pharmacol 1999; 33: 605-10.
83. Tindall H, Tooke JE, Menys VC et al. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin blood flow following cold challenge in patients with Raynaud's phenomenom. Eur J Clin Invest 1985; 15: 20-23.
84. Pancera P, Sansone S, Secchi S, Covi G, Lechi A. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon. J Intern Med 1997; 242: 373-76.
85. Dalsgaard CJ, Jernbeck J, Stains W et al. Calcitonin gene-related peptide-like immunoreactivity in nerve fibers in the human skin. Relation to fibers containing substance P-, somatostatin- and vasoactive intestinal polypeptide-like immunoreactivity. Histochemistry 1989; 91: 35-38.
86. Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990; 336: 1530-33.
87. Bunker CB, Goldsmith PC, Leslie TA, Hayes N, Foreman JC, Dowd PM. Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud's phenomenon. Br J Dermatol 1996; 134: 399-406.
88. Bunker CB, Coulson ML, Hayes NA, Dowd PM, Foreman JC. Further studies on the actions of endothelin-1 on blood flow in human skin. Br J Dermatol 1992; 127: 85-90.
89. Holzer P, Jocic M, Peskar BA. Mediation by prostaglandins of the nitric oxide-induced neurogenic vasodilatation in rat skin. Br J Pharmacol 1995; 116: 2365-70.
90. Klede M, Clough G, Lischetzki G, Schmelz M. The effect of the nitric oxide synthase inhibitor N-nitro-L-arginine-methyl ester on neuropeptide-induced vasodilation and protein extravasation in human skin. J Vasc Res 2003; 40: 105-14.
91. Warner TD, Mitchell JA, de Nucci G, Vane JR. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol 1989; 13 (suppl 5): S85-88.
92. Tan FK, Arnett FC. Genetic factors in the etiology of systemic sclerosis and Raynaud phenomenon. Curr Opin Rheumatol 2000; 12: 511-19.
93. Susol E, MacGregor AJ, Barrett JH et al. A two-stage genomewide screen for susceptibility loci in primary Raynaud's phenomenon. Arthritis Rheum 2000; 43: 1641-46.
94. Bedarida G, Kim D, Blaschke TF, Hoffman BB. Venodilation in Raynaud's disease. Lancet 1993; 342: 1451-54.